Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. A semaphorin-plexin-Rasal1 signaling pathway inhibits gastrin expression and protects against peptic ulcers

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Delivery mode and gut microbial changes correlate with an increased risk of childhood asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Predicting functional effects of missense variants in voltage-gated sodium and calcium channels

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Distinct immune phenotypes in infants developing asthma during childhood

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Mathieu Gigoux
  • Morten O. Holmström
  • Roberta Zappasodi
  • Joseph J. Park
  • Stephane Pourpe
  • Cansu Cimen Bozkus
  • Levi M.B. Mangarin
  • David Redmond
  • Svena Verma
  • Sara Schad
  • Mariam M. George
  • Divya Venkatesh
  • Arnab Ghosh
  • David Hoyos
  • Zaki Molvi
  • Baransel Kamaz
  • Anna E. Marneth
  • William Duke
  • Matthew J. Leventhal
  • Max Jan
  • Vincent T. Ho
  • Gabriela S. Hobbs
  • Trine Alma Knudsen
  • Vibe Skov
  • Lasse Kjær
  • Thomas Stauffer Larsen
  • Dennis Lund Hansen
  • R. Coleman Lindsley
  • Hans Hasselbalch
  • Jacob H. Grauslund
  • Thomas L. Lisle
  • Özcan Met
  • Patrick Wilkinson
  • Benjamin Greenbaum
  • Manuel A. Sepulveda
  • Timothy Chan
  • Raajit Rampal
  • Mads H. Andersen
  • Omar Abdel-Wahab
  • Nina Bhardwaj
  • Jedd D. Wolchok
  • Ann Mullally
  • Taha Merghoub
Vis graf over relationer

The majority of JAK2V617F-negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin (CALR), resulting in a common carboxyl-terminal mutant fragment (CALRMUT), representing an attractive source of neoantigens for cancer vaccines. However, studies have shown that CALRMUT-specific T cells are rare in patients with CALRMUT MPN for unknown reasons. We examined class I major histocompatibility complex (MHC-I) allele frequencies in patients with CALRMUT MPN from two independent cohorts. We observed that MHC-I alleles that present CALRMUT neoepitopes with high affinity are underrepresented in patients with CALRMUT MPN. We speculated that this was due to an increased chance of immune-mediated tumor rejection by individuals expressing one of these MHC-I alleles such that the disease never clinically manifested. As a consequence of this MHC-I allele restriction, we reasoned that patients with CALRMUT MPN would not efficiently respond to a CALRMUT fragment cancer vaccine but would when immunized with a modified CALRMUT heteroclitic peptide vaccine approach. We found that heteroclitic CALRMUT peptides specifically designed for the MHC-I alleles of patients with CALRMUT MPN efficiently elicited a CALRMUT cross-reactive CD8+ T cell response in human peripheral blood samples but not to the matched weakly immunogenic CALRMUT native peptides. We corroborated this effect in vivo in mice and observed that C57BL/6J mice can mount a CD8+ T cell response to the CALRMUT fragment upon immunization with a CALRMUT heteroclitic, but not native, peptide. Together, our data emphasize the therapeutic potential of heteroclitic peptide-based cancer vaccines in patients with CALRMUT MPN.

OriginalsprogEngelsk
Artikelnummereaba4380
TidsskriftScience translational medicine
Vol/bind14
Udgave nummer649
Sider (fra-til)eaba4380
ISSN1946-6234
DOI
StatusUdgivet - 15 jun. 2022

ID: 79292482